Patents Assigned to Hydra Biosciences
  • Substituted xanthines and methods of use thereof
    Patent number: 11958854
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: April 16, 2024
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20230040259
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 9, 2023
    Applicant: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Inhibitors of TRPC6
    Patent number: 11485740
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 1, 2022
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • NOVEL SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20220177479
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 9, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20220056032
    Abstract: The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: December 10, 2019
    Publication date: February 24, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • Substituted xanthines and methods of use thereof
    Patent number: 11208409
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: December 28, 2021
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity
    Patent number: 11198696
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: December 14, 2021
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • INHIBITORS OF TRPC6
    Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Inhibitors of TRPC6
    Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Substituted xanthines and methods of use thereof
    Patent number: 10399982
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 3, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Substituted xanthine derivatives
    Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10221177
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 5, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9980968
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 29, 2018
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Jayhong A. Chong
  • Substituted xanthines and methods of use thereof
    Patent number: 9969736
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 15, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9951073
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 24, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventor: Jayhong A. Chong
  • METHODS AND COMPOSITIONS FOR TREATING PAIN
    Publication number: 20180093986
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 5, 2018
    Applicants: Hydra Biosciences, Inc., Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Methods and compositions for treating anxiety
    Patent number: 9895356
    Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 20, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng
  • Methods and compositions for treating pain
    Patent number: 9815838
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: November 14, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen Mcnamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Quinazoline-2,4(1 H,3H)-dione derivatives
    Patent number: 9745272
    Abstract: This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: August 29, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Inhibitors of TRPC6
    Patent number: RE49699
    Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu